Evidence mapPaperPMID 41346597Full record

ReviewFrontiers in immunology2025

The role of the microbiota-gut-brain axis in schizophrenia: an immunological perspective.

Bo-Wei Su, Yao Li, Le-Ying Yang, Hai-Xia Yang, Wen-Hao Wang, Hui-Wen Ren, Ya-Nan Bao, Jia-Yi Lao, Zhi-Lin Luan

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bo-Wei Su *Advanced Institute for Medical Sciences, Dalian Medical University, Dalian, China.
Yao Li *Department of Neuroregulation Center, Southwest Rehabilitation Hospital, Chengdu, China.
Le-Ying YangSchool of Education, University of New South Wales, Sydney, NSW, Australia.
Hai-Xia YangAdvanced Institute for Medical Sciences, Dalian Medical University, Dalian, China.
Wen-Hao WangAdvanced Institute for Medical Sciences, Dalian Medical University, Dalian, China.
Hui-Wen RenAdvanced Institute for Medical Sciences, Dalian Medical University, Dalian, China.
Ya-Nan BaoAdvanced Institute for Medical Sciences, Dalian Medical University, Dalian, China.
Jia-Yi LaoAdvanced Institute for Medical Sciences, Dalian Medical University, Dalian, China.
Zhi-Lin LuanAdvanced Institute for Medical Sciences, Dalian Medical University, Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia (SZ) is a severe neuropsychiatric disorder arising from complex interactions between genetic susceptibility and environmental factors. There is growing evidence that immune dysregulation and neuroinflammation are central to its pathogenesis, with the microbiota-gut-brain (MGB) axis playing a critical role. This review synthesizes clinical and preclinical findings to elucidate the relationship between gut microbiota dysbiosis and aberrant inflammatory signaling in the periphery and central nervous system in schizophrenia. We detail how alterations in gut microbiota metabolites, following dysbiosis disrupt blood-brain barrier (BBB) integrity and exacerbate neuroinflammation, ultimately leading to the neuropathology of SZ. The review further explores how gut dysbiosis activates innate immune pathways, including the complement system (e.g., C4) and Toll-like receptors (e.g., TLR4), and examines the bidirectional relationship between cytokine imbalances and gut microbiota. A key focus is placed on the dysregulation of the kynurenine pathway of tryptophan metabolism, which mechanistically links immune activation to neurotransmitter imbalances. Collectively, these findings demonstrate that gut microbiota dysbiosis contributes to the pathophysiology of schizophrenia through multifaceted immune-neuro-endocrine pathways, highlighting the MGB axis as a promising target for novel therapeutic strategies.

Indexed as

BrainBrain-Gut AxisGastrointestinal MicrobiomeSchizophreniaAnimalsBlood-Brain BarrierDysbiosisHumanscomplement systemgut microbiota metabolitesimmune dysregulationkynurenine pathwaymicrobiota-gut-brain axisneuroinflammationschizophreniatoll-like receptors

Identifiers

PMID41346597
PMCPMC12672538

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.